secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lantheus Holdings, Inc. (LNTH)
CIK:        0001521036
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001193125-26-210369
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lantheus Q1 revenue $377.3M (+1.2% YoY); GAAP EPS $1.80, adjusted EPS $1.46
---------------------------------------------------------------------------

- Worldwide revenue $377.3M (+1.2%); GAAP diluted EPS $1.80 (+76.5%), adjusted diluted EPS $1.46 (-4.6%).
- PYLARIFY sales $240.9M (-6.5% YoY); DEFINITY $84.6M (+6.8%); Neuraceq $35.4M.
- FDA approved PYLARIFY TruVu (new formulation); phased launch begins Q4 2026.
- FDA tentative approval for PNT2003 (Lutetium Lu 177 Dotatate radioequivalent for GEP-NETs); launch pending.
- Reaffirmed FY2026 guidance: revenue $1.4B-$1.45B, adjusted EPS $5.00-$5.25.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1521036/000119312526210369/0001193125-26-210369-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1521036/000119312526210369/lnth-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-210369

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer